Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
06:30am, Wednesday, 17'th Apr 2024
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
07:05pm, Monday, 15'th Apr 2024
Vanda Pharmaceuticals (VNDA) concluded the recent trading session at $4.06, signifying a -1.46% move from its prior day's close.
Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:21pm, Wednesday, 10'th Apr 2024
Vanda Pharmaceuticals (VNDA) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
08:56am, Thursday, 04'th Apr 2024
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder
01:05pm, Wednesday, 03'rd Apr 2024
Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.
Vanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disorder
07:11pm, Tuesday, 02'nd Apr 2024
Shares of Vanda Pharmaceuticals VNDA, -5.10% jumped 33% to $5.23 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associa
US FDA approves Vanda's drug for bipolar disorder
06:15pm, Tuesday, 02'nd Apr 2024
The U.S. FDA approved Vanda Pharmaceuticals' drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatme
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
11:51am, Thursday, 07'th Mar 2024
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
10:59pm, Monday, 12'th Feb 2024
Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material cat
Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
01:20pm, Monday, 12'th Feb 2024
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript
05:51pm, Wednesday, 07'th Feb 2024
Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Earnings Call Transcript
09:36pm, Wednesday, 08'th Nov 2023
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Kevin Moran - SVP, CFO and Treasurer Dr. Mihael Polymeropoulos - President, C
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
06:47pm, Wednesday, 08'th Nov 2023
Vanda Pharmaceuticals (VNDA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.06 per share a year ago.
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
05:30pm, Wednesday, 06'th Sep 2023
WASHINGTON , Sept. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday
02:36pm, Tuesday, 05'th Sep 2023
Vanda is being dropped from the S&P 600 SmallCap 600. The company is suing the federal government over what it says was the release of trade secrets regarding its therapies.
